Bioasis Technologies Inc.
BIOAF · OTC
11/30/2022 | 8/31/2022 | 5/31/2022 | 2/28/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | -0.01 | 0.29 | 0.15 |
| FCF Yield | -3.39% | -1.74% | -3.65% | -3.53% |
| EV / EBITDA | -22.77 | -17.22 | 638.11 | -12.26 |
| Quality | ||||
| ROIC | 205.21% | -231.54% | 266.70% | -275.20% |
| Gross Margin | -48.29% | 73.99% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.45 | 0.21 | 2.53 | 1.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -59.70% | -66.74% | -55.10% | -60.43% |
| Free Cash Flow Growth | -98.18% | 62.02% | 13.48% | 28.04% |
| Safety | ||||
| Net Debt / EBITDA | -3.10 | -1.73 | 37.51 | -0.11 |
| Interest Coverage | -3.30 | -3.91 | -2.55 | -8.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -749.04 | -4,412.34 | -8,020.29 | -9,816.29 |